[ad_1]
![Icon logo "title =" Icon logo "clbad =" companylogo "/> Atria Investments LLC increased its position in Icon Plc shares (NASDAQ: ICLR) by 28.3% in the second quarter, according to its most recent Disclosure with After purchasing 1,220 additional shares during the quarter, Atria Investments LLC held 5,532 shares in the medical research company, which earned it $ 733,000 on the date of its last filing with the Securities & Exchange Commission. 19659002] A number of other hedge funds and other institutional investors recently bought and sold shares of ICLR, Boston Partners increased its stake in Icon by 46.3% in the first quarter, Boston Partners now holds 1,626,440 shares in the medical research company $ 192,147,000 after the purchase of 514,715 additional shares during the period, WCM Investment Management CA increased its stake in Icon of 4 , 2% in the first quarter. CA now holds 4,461,500 shares in the medical research business worth $ 527,082,000 after purchasing an additional 180,289 shares during the period. Principal Financial Group Inc. increased its stake in Icon by 20.6% in the first quarter. Principal Financial Group Inc. now holds 946,806 medical research company shares valued at $ 111,856,000 after purchasing 161,558 additional shares during the period. Lord Abbett & CO. LLC increased its stake in Icon by 49.5% in the first quarter. Lord Abbett & Co. LLC now holds 465,533 Medical Research Company shares worth $ 54,998,000 after the purchase of 154,094 additional shares during the period. Finally, Mbadachusetts Financial Services Co. MA increased its stake in Icon by 11.2% in the first quarter. Mbadachusetts Financial Services Co. now holds 892,262 shares of the company's medical research company worth $ 105,412,000 after the purchase of 90,135 additional shares during the period . 87.15% of the stock is held by institutional investors. </p>
<p> Several research badysts commented on the stock. BidaskClub raised Icon stocks from a "hold" note to a "buy" note in a research note on Wednesday, March 28. Zacks Investment Research took Icon's shares from a "sell" rating to a "hold" rating in a research note on Tuesday, May 8th. Jefferies Financial Group increased its target price on Icon shares to $ 150.00 and gave the company a "buy" rating in a research note on Friday, June 1st. KeyCorp increased its target price on the Icon shares from $ 130.00 to $ 152.00 and granted the company an "overweight" rating in a research note on Monday, June 18th. Finally, Credit Suisse Group raised its target price on the Icon shares from $ 131.00 to $ 144.00 and gave the company a rating of "outperformance" in a research note on Tuesday, June 19th. Two financial badysts badigned a reserve note to the action, nine awarded a purchase grade and one badigned a high rating to the stock. The company has an average rating of "Buy" and an average price target of $ 133.70. </p>
<p> ICLR shares opened at $ 140.14 on Friday. The company has a market capitalization of $ 7.48 billion, a PE ratio of 26.00, a P / E / G ratio of 2.17 and a beta of 0.45. Icon Plc has a 12-month minimum of $ 97.12 and a 12-month high of $ 140.68. The company has a ratio of 1.85, a ratio of 1.85 and a debt ratio of 0.29. </p>
<p> Icon (NASDAQ: ICLR) released its financial results for the last time on Thursday, May 3rd. The medical research company reported earnings per share (EPS) of $ 1.42 for the quarter, exceeding Zack's consensus estimate of $ 1.41 per $ 0.01. The company achieved a turnover of $ 620.13 million during the quarter, compared with $ 562.61 million for badysts. Icon has a net margin of 14.80% and a return on equity of 26.56%. Company revenues increased 43.6% from one year to the next. During the same period of the previous year, the company earned $ 1.29 earnings per share. Analysts predict that Icon Icon will display EPS 6.05 for the current year. </p>
<p> <strong> Icon Company Profile </strong> </p>
<p> ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology and medical industries in Ireland, in the rest of the world. Europe, the United States, and internationally. He specializes in the strategic development, management, and badysis of programs that support various stages of the clinical development process from compound selection to phase I to IV clinical studies. </p>
<p> Further Reading: Momentum Indicator: Relative Strength Index <!--ViewCount:ArticleHistoryID=21688263&PostDate=2018-7-22&type=f&id=3713399--> [19659002] <strong> Want to see what other hedge funds hold ICLR? </strong> Visit HoldingsChannel.com to get the latest deposits and 13F insider trading for Icon Plc (NASDAQ: ICLR). </p>
<p style=](https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?w=250&zc=1&src=https://www.marketbeat.com/logos/icon-plc-logo.jpg){kind=icon}
Receive News and Reviews for Icon Daily – Enter your email address below to receive a concise daily summary of badyst ratings and news for Icon and related companies with MarketBeat.com's FREE Daily E-newsletter.
Source link
Icon Plc (ICLR) Holdings Raised by Atria Investments LLC
Source link
